Europe Point of Care Diagnostics Market

The report "Europe Point of Care Diagnostics Market by Product [Glucose, Infectious Disease (TB, HAI, STD), Pregnancy], Purchase Mode (Rx, OTC), Technology [Biochemistry, MDx (RT-PCR, INAAT)], Sample (Blood, Urine), End User (Home Care, Hospitals) - Forecast to 2031", is estimated at USD 4.45 billion in 2026 and is forecasted to reach USD 7.17 billion by 2031 at a CAGR of 10.0%.

Browse 130 market data Tables and 54 Figures spread through 200 Pages and in-depth TOC on "Europe Point of Care Diagnostics Market by Product [Glucose, Infectious Disease (TB, HAI, STD), Pregnancy], Purchase Mode (Rx, OTC), Technology [Biochemistry, MDx (RT-PCR, INAAT)], Sample (Blood, Urine), End User (Home Care, Hospitals) - Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/europe-point-of-care-diagnostics-market-162944391.html

The Europe PoC testing market is experiencing high growth due to the rising incidence of diseases like CVD and diabetes. The increasing incidence of chronic diseases has raised the need for quick and convenient PoC testing solutions to enable efficient management of the disease. Moreover, the increasing availability and acceptance of CE-marked point-of-care tests have fueled their adoption in healthcare settings. Increased healthcare expenditure on screening and prevention campaigns and the continued shift towards decentralization and community-based healthcare practices have also improved access to diagnostic testing. These collective initiatives to enable early diagnosis, improve the efficiency of the healthcare system, and provide cost-effective healthcare solutions while improving health outcomes have significantly driven the demand for point-of-care diagnostics in Europe.

Prescription-based testing products have registered the largest market share by mode of purchase.

The European point-of-care diagnostics market is divided into over-the-counter testing products and prescription-based testing products. Prescription-based point-of-care tests are widely accepted in European hospitals, clinics, and primary healthcare facilities and are also an essential tool in the diagnosis and treatment of various diseases. The increasing incidence of diseases such as diabetes, cardiovascular diseases, and infectious diseases has led to an increase in the demand for prescription-based POC tests, as these tests have high diagnostic accuracy and are also essential for proper clinical decision-making. In addition, strict adherence to European standards ensures that the quality of prescription-based point-of-care tests remains consistent, thus increasing the acceptance of prescription-based point-of-care tests in the European market.

Home care settings and self-testing account for the largest end-user market.

The growing need for patient convenience, comfort, and decentralized healthcare delivery has led to the increased adoption of home care and self-testing solutions in Europe. These solutions enable patients to test their health conditions without visiting healthcare facilities repeatedly, which is especially beneficial for patients suffering from chronic diseases like diabetes. The ease of getting rapid results, along with the improvements that have been made in the accuracy and affordability of home-based testing solutions, has led to the increased adoption of home-based testing solutions. Home care and self-testing solutions have been a major and rapidly growing end-user segment for the European point-of-care diagnostics market due to the growing prevalence of chronic diseases and the increasing need for preventive care and self-management.

The major players operating in this market are Siemens (Germany), Abbott Diagnostics (US),  Danaher Corporation (US), F. Roche Ltd (Switzerland), Quidel Corporation (US), Thermo Fisher (US), Becton, Dickinson and Company (US), BIOSYNEX (France), bioMérieux (France), and EKF Diagnostics (UK).

Don’t miss out on business opportunities in Europe Point of Care Diagnostics Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/